Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Target Price at $26.44

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has received a consensus rating of "Hold" from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $26.44.

A number of equities analysts have issued reports on PCRX shares. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. HC Wainwright raised their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Finally, Needham & Company LLC reduced their price target on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th.

Insider Buying and Selling at Pacira BioSciences

In other news, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the sale, the senior vice president now directly owns 59,564 shares in the company, valued at $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Pacira BioSciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. purchased a new stake in shares of Pacira BioSciences during the first quarter worth about $32,506,000. Point72 Asset Management L.P. purchased a new stake in shares of Pacira BioSciences during the fourth quarter worth about $20,266,000. American Century Companies Inc. increased its stake in shares of Pacira BioSciences by 392.2% during the first quarter. American Century Companies Inc. now owns 667,423 shares of the company's stock worth $16,585,000 after purchasing an additional 531,831 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Pacira BioSciences during the first quarter worth about $12,884,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Pacira BioSciences during the fourth quarter worth approximately $8,558,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Pacira BioSciences Stock Performance

PCRX traded up $0.08 during trading on Wednesday, reaching $24.23. 668,087 shares of the company's stock were exchanged, compared to its average volume of 963,755. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $29.61. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99. The stock has a market capitalization of $1.12 billion, a P/E ratio of -10.63 and a beta of 0.52. The company's fifty day simple moving average is $25.47 and its 200-day simple moving average is $23.86.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.